Apotex Pharmachem Inc.

Other

Biocon Limited

Kiran Kumar Kothakonda

Daqing Che

Bhaskar Reddy Guntoori

Alfredo Paul Ceccarelli

Allan W Rey

Yajun Zhao

Fan Wang

Sammy Chris Duncan

Uma Kotipalli

Minh T N Nguyen

Laura Kaye Montemayor

Anegondi Sreenivasa Prasad

Kaarina K Milnes

Kevin Wade Kells

Srinivas Pullela Venkata

Ganesh Ekambaram

There is provided processes for preparing Lubiprostone and intermediates thereof. Also provided are compounds, including intermediates for preparing Lubiprostone as well compositions comprising Lubiprostone and other compounds, including intermediates for preparing Lubiprostone and other compounds. (I) 

Methods of making lubiprostone and intermediates thereof

The present disclosure discloses processes of Everolimus and intermediates: reacting Sirolimus (Rapamycin) under solvent free conditions with appropriate side chain implying portion wise additions, one pot conversion, and resin mediated synthesis.

Processes for preparation of Everolimus and intermediates thereof

Provided for in the instant application are two additional polymorphic forms of rifaximin; namely substantially pure APO-I and APO-II. Also provided are processes for preparing substantially pure APO-I and APO-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused bybacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery.

Polymorphic forms of Rifaximin

There is provided a crystalline form of Lubiprostone, termed APO-II and methods for making APO-II. APO-II is a polymorphic form of Lubiprostone.

Polymorphic forms of Lubiprostone

There is provided a process for the preparation of olanzapine comprising:

Processes for the synthesis of olanzapine

A stable amorphous form of rifaximin is disclosed. This form is chemically and polymorphically stable on storage and can be prepared by dissolving rifaximin in a solvent to form a solution, which is precipitated by adding an anti-solvent and isolating of the precipitated amorphous rifaximin as an end product.

Amorphous form of rifaximin and processes for its preparation

Growing community of inventors

Brantford, Canada

Kiran Kumar Kothakonda